Bynfezia

Generic name:octreotide acetate
Dosage form: subcutaneous injection
Drug class:Somatostatin and somatostatin analogs

Medically reviewed by Drugs.com. Last updated on Jan 24, 2022.

Indications and Usage for Bynfezia

Acromegaly

Bynfezia Pen is indicated to reduce blood levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) [somatomedin C] in adult patients with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.

Carcinoid Tumors

Bynfezia Pen is indicated for the treatment of adult patients with severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

Vasoactive Intestinal Peptide Tumors (VIPomas)

Bynfezia Pen is indicated for the treatment of adult patients with the profuse watery diarrhea associated with VIP-secreting tumors.

Limitations of Use

In patients with acromegaly, the effect of Bynfezia Pen on improvement in clinical signs and symptoms, reduction in tumor size, and rate of growth has not been determined.

In patients with carcinoid syndrome and VIPomas, the effect of Bynfezia Pen on the tumor size, rate of growth and development of metastases has not been determined.

Bynfezia Dosage and Administration

Laboratory Testing Prior to Bynfezia Pen Initiation

• Assess baseline thyroid function before initiation of Bynfezia Pen therapy and monitor periodically [see Warnings and Precautions (5.3)].

Recommended Dosage in Acromegaly

• Initiate dosing at 50 mcg subcutaneously three times a day to improve tolerability to gastrointestinal adverse reactions [see Adverse Reactions (6.1)].
• Measure IGF-I levels every 2 weeks after Bynfezia Pen initiation or dosage change to guide titration. Alternatively, measuring g...